|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then examined the effect of HN.49 on the enzyme activity of MMP9 and the migration activity of osteosarcoma cells in vitro.
|
25177029 |
2014 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the gene expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in OS cell lines treated by the GA.
|
23175213 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amentoflavone significantly inhibits tumor growth and reduces protein levels of phospho-extracellular signal-regulated kinase (P-ERK), nuclear factor-kappaB (NF-κB) p65 (Ser536), vascular endothelial growth factor (VEGF), matrix metallopeptidase 9 (MMP-9), X-linked inhibitor of apoptosis protein (XIAP), and cyclin-D1 in osteosarcoma in vivo.
|
31262893 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On gelatinase zymography, osteosarcoma MNNG-HOS showed a band corresponding to MMP-2 and induction of MMP-9 with PMA (100 ng/ml) treatment.
|
23900236 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metformin suppressed OS MG63 cell proliferation in a dose- and time-dependent manner and markedly blocked anti-metastatic potentials, migration, and invasion, by downregulating matrix metalloproteinase 2 (MMP2) and MMP9.
|
26164004 |
2015 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of meta-analysis indicated that MMP-9 may be a prognostic biomarker guiding the clinical therapy for OS.
|
30383677 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma and rhabdomyosarcoma showed bands corresponding to MMP-2 and -9 with dose-dependent enhancement of MMP-9 with phorbol 12-myristate 13-acetate (PMA) treatment.
|
24190483 |
2014 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, it altered the expression of various proteins associated with cell growth (Ki67, p21, cyclin A, cyclin E, and cyclin-dependent kinase 2), migration (matrix metalloproteinase-2 [MMP-2], MMP-9, and tissue inhibitor of metalloproteinase-1), apoptosis (poly[ADP-ribose] polymerase 1 and caspase 3), and drug resistance (p-glycoprotein 1, lung resistance-related protein 1, growth arrest and DNA damage-45α, glutathione S-transferase π, and heat shock protein 27) in paclitaxel-resistant osteosarcoma cells.
|
31106479 |
2019 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study therefore demonstrates that the downregulation of MMP-9 mRNA by VPA plays a role in the inhibitory action of VPA on the secretion of soluble MICA and MICB in osteosarcoma cells.
|
22923031 |
2012 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found a pronounced suppressive effect of glucosamine sulfate particularly on MMP-3 and also MMP-9 mRNA and protein levels in osteosarcoma cell lines in vitro.
|
27562075 |
2016 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A reporter gene assay demonstrated that BITC, PEITC, and SFN suppressed TAP-induced MMP-9 expression by inhibiting AP-1 and NF-κB in U20S osteosarcoma cells.
|
28969043 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We provide evidence in our cell model that the relaxin siRNA down-regulated the expression of MMP-9 and the MMP-9 activity, suggesting that relaxin may promote the proliferation, invasion and metastasis of osteosarcoma cells by regulating the expression of MMP-9 and facilitating ECM degradation.
|
23661525 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo experiments demonstrated that knockdown of HOTAIR could notably suppress cellular proliferation, inhibit invasion and decrease the secretion of MMP2 and MMP9 in osteosarcoma.
|
25728753 |
2015 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exogenous treatment of osteosarcoma cells with WISP-1 promoted cell motility and matrix metalloproteinase (MMP)-2 and MMP-9 expression.
|
24036215 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The positive rates of CD44s, MMP-9, and Ki-67 in osteosarcoma were 71.0%, 75.8%, and 35.5%, respectively, which were significantly higher than that in control tissue.
|
12479099 |
2002 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that CD151 knockdown inhibits the expression of MMP9 through the GSK-3β/β‑catenin pathway and also inhibits OS migration and invasion in vitro and metastasis in vivo in highly metastatic OS.
|
26707073 |
2016 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High levels of CUL1 promote osteosarcoma progression via up-regulation of MMP9 expression.
|
28315506 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When BMP-9 expression was enhanced, the expression of PI3Kp85α, p-AKT, Ki-67 and MMP-9 was downregulated in osteosarcoma cells.
|
22948234 |
2012 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAP1 on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively).
|
23527718 |
2013 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used bioinformatics tools to identify possible binding sites of miR-491 in the 3'UTR of MMP9 and 30 OS tissue samples were collected and divided into two groups based on the rs1056629 genotype (AA, N=20; AC, N=8; and CC N=2).
|
27023472 |
2016 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Medium conditioned by mouse osteosarcoma cells overexpressing Twist2 inhibited expression of the MMP9 gene as well as invasion in mouse embryonic fibroblasts, and forced expression of Twist2 in osteosarcoma cells suppressed MMP9 gene expression in tumor tissue.
|
23557174 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell viabilities were determined using MTT assay, the mRNA levels of MMP-2 and MMP-9 were analyzed by reverse-transcription polymerase chain reaction, the amount of MMP-2 and MMP-9 protein were analyzed by Westernblot, the activities of MMP-2 and MMP-9 were observed by Gelatin zymography, and Matrigel invasion assays were used to investigate the invasive potential of osteosarcoma cell lines before and after risedronate treatment.
|
19624845 |
2009 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After SOX4 gene silencing, the protein expression levels of Bax, Caspase-3, and P53 in osteosarcoma cells were significantly elevated, while the protein expression levels of Bcl-2, MMP2, and MMP9 were obviously decreased.
|
29038881 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, 14‑3‑3β knockdown significantly decreased the protein expression levels of β‑catenin, cyclin D1, v‑myc avian myelocytomatosis viral oncogene homolog and matrix metallopeptidase 9 in osteosarcoma MG63 cells.
|
29207109 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, we hypothesize that BMP9 inhibits the migration and invasiveness of OS cells through a Smad-dependent pathway by downregulating the expression and activity of MMP9.
|
23807047 |
2013 |